Literature DB >> 31980730

Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells.

Hein Than1,2, Anthony D Pomicter1, Dongqing Yan1, Larry P Beaver1, Anna M Eiring1, William L Heaton1, Anna Senina1, Phillip M Clair1, Sharon Shacham3, Clinton C Mason4, Thomas O' Hare1,5, Michael W Deininger6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31980730      PMCID： PMC7364821          DOI： 10.1038/s41375-020-0708-1

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Authors:  Susanne Saussele; Johan Richter; Joelle Guilhot; Franz X Gruber; Henrik Hjorth-Hansen; Antonio Almeida; Jeroen J W M Janssen; Jiri Mayer; Perttu Koskenvesa; Panayiotis Panayiotidis; Ulla Olsson-Strömberg; Joaquin Martinez-Lopez; Philippe Rousselot; Hanne Vestergaard; Hans Ehrencrona; Veli Kairisto; Katerina Machová Poláková; Martin C Müller; Satu Mustjoki; Marc G Berger; Alice Fabarius; Wolf-Karsten Hofmann; Andreas Hochhaus; Markus Pfirrmann; Francois-Xavier Mahon
Journal:  Lancet Oncol       Date:  2018-05-04       Impact factor: 41.316

2.  LocNES: a computational tool for locating classical NESs in CRM1 cargo proteins.

Authors:  Darui Xu; Kara Marquis; Jimin Pei; Szu-Chin Fu; Tolga Cağatay; Nick V Grishin; Yuh Min Chook
Journal:  Bioinformatics       Date:  2014-12-15       Impact factor: 6.937

3.  Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription.

Authors:  Weiqi Huang; Wei Zhou; Gurveen Saberwal; Iwona Konieczna; Elizabeth Horvath; Efstratios Katsoulidis; Leonidas C Platanias; Elizabeth A Eklund
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

4.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Authors:  Amie S Corbin; Anupriya Agarwal; Marc Loriaux; Jorge Cortes; Michael W Deininger; Brian J Druker
Journal:  J Clin Invest       Date:  2010-12-13       Impact factor: 14.808

5.  Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML.

Authors:  Florian H Heidel; Lars Bullinger; Zhaohui Feng; Zhu Wang; Tobias A Neff; Lauren Stein; Demetrios Kalaitzidis; Steven W Lane; Scott A Armstrong
Journal:  Cell Stem Cell       Date:  2012-04-06       Impact factor: 24.633

6.  shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.

Authors:  Jamshid S Khorashad; Anna M Eiring; Clinton C Mason; Kevin C Gantz; Amber D Bowler; Hannah M Redwine; Fan Yu; Ira L Kraft; Anthony D Pomicter; Kimberly R Reynolds; Anthony J Iovino; Matthew S Zabriskie; William L Heaton; Srinivas K Tantravahi; Michael Kauffman; Sharon Shacham; Alex Chenchik; Kyle Bonneau; Katharine S Ullman; Thomas O'Hare; Michael W Deininger
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

7.  Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources.

Authors:  Susan M Graham; J Keith Vass; Tessa L Holyoake; Gerard J Graham
Journal:  Stem Cells       Date:  2007-08-23       Impact factor: 6.277

8.  Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

Authors:  Christopher J Walker; Joshua J Oaks; Ramasamy Santhanam; Paolo Neviani; Jason G Harb; Gregory Ferenchak; Justin J Ellis; Yosef Landesman; Ann-Kathrin Eisfeld; Nash Y Gabrail; Carrie L Smith; Michael A Caligiuri; Peter Hokland; Denis Claude Roy; Alistair Reid; Dragana Milojkovic; John M Goldman; Jane Apperley; Ramiro Garzon; Guido Marcucci; Sharon Shacham; Michael G Kauffman; Danilo Perrotti
Journal:  Blood       Date:  2013-08-22       Impact factor: 22.113

9.  KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.

Authors:  J Etchin; A Berezovskaya; A S Conway; I A Galinsky; R M Stone; E Baloglu; W Senapedis; Y Landesman; M Kauffman; S Shacham; J C Y Wang; A T Look
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

10.  Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia.

Authors:  Neetu Singh; Anil Kumar Tripathi; Dinesh Kumar Sahu; Archana Mishra; Margaret Linan; Bianca Argente; Julia Varkey; Niranjan Parida; Rebecca Chowdhry; Hari Shyam; Nawazish Alam; Shivani Dixit; Pratap Shankar; Abhishek Mishra; Avinash Agarwal; Chris Yoo; Madan Lal Brahma Bhatt; Ravi Kant
Journal:  Oncotarget       Date:  2018-07-13
View more
  2 in total

1.  MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis.

Authors:  Helong Zhao; Anthony D Pomicter; Anna M Eiring; Anca Franzini; Jonathan Ahmann; Jae-Yeon Hwang; Anna Senina; Bret Helton; Siddharth Iyer; Dongqing Yan; Jamshid S Khorashad; Matthew S Zabriskie; Anupriya Agarwal; Hannah M Redwine; Amber D Bowler; Phillip M Clair; Shannon K McWeeney; Brian J Druker; Jeffrey W Tyner; Derek L Stirewalt; Vivian G Oehler; Sooryanarayana Varambally; Kristofer C Berrett; Jeffery M Vahrenkamp; Jason Gertz; Katherine E Varley; Jerald P Radich; Michael W Deininger
Journal:  Blood       Date:  2022-02-03       Impact factor: 22.113

2.  A genome-wide CRISPR-Cas9 screen identifies CENPJ as a host regulator of altered microtubule organization during Plasmodium liver infection.

Authors:  Kamalakannan Vijayan; Nadia Arang; Ling Wei; Robert Morrison; Rechel Geiger; K Rachael Parks; Adam J Lewis; Fred D Mast; Alyse N Douglass; Heather S Kain; John D Aitchison; Jarrod S Johnson; Alan Aderem; Alexis Kaushansky
Journal:  Cell Chem Biol       Date:  2022-06-22       Impact factor: 9.039
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.